Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Background: We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl) inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson’s disease dementia or dementia with Lewy bodies. Objectives: The primary outcomes of this study were safety and tolerability; pharmacokinetics and target engagement were secondary, while clinical outcomes were exploratory. Methods: Twelve subjects were randomized into 150 mg ( n = 5) or 300 mg ( n = 7) groups and received Nilotinib orally every day for 24 weeks. Results: This study shows that 150 mg and 300 mg doses of Nilotinib appear to be safe and tolerated in subjects with advanced Parkinson’s disease. Nilotinib is detectable in the cerebrospinal fluid (CSF) and seems to engage the target Abl. Motor and cognitive outcomes suggest a possible beneficial effect on clinical outcomes. The CSF levels of homovanillic acid are significantly increased between baseline and 24 weeks of treatment. Exploratory CSF biomarkers were measured. Conclusions: This small proof-of-concept study lacks a placebo group and participants were not homogenous, resulting in baseline differences between and within groups. This limits the interpretations of the biomarker and clinical data, and any conclusions should be drawn cautiously. Nonetheless, the collective observations suggest that it is warranted to evaluate the safety and efficacy of Nilotinib in larger randomized, double-blind, placebo-controlled trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nilotinib, proven to improve mitochondrial function,517 and clinical trials have been initiated to explore its application in PD.518,519”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [519]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance
Lonskaya, I., Desforges, N. M., Hebron, M. L., & Moussa, C. E.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083914 · Cited by 86
Self-citationRetractedRepertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Boland, B., Kumar, A., Lee, S., Platt, F. M., Wegiel, J., Yu, W. H., & Nixon, R. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0800-08.2008 · Cited by 1,119
Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy
Ravikumar, B. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.9.1107 · Cited by 1,111
DJ‐1 has a role in antioxidative stress to prevent cell death
Taira, T., Saito, Y., Niki, T., Iguchi‐Ariga, S. M. M., Takahashi, K., & Ariga, H. (2004) · EMBO reports · doi:10.1038/sj.embor.7400074 · Cited by 853
Research works printed but not linked: 2
- 10.1007/s00109-013-1112-3 · DOI · Paper page
- Kang JH, 2013, JAMA Neurol, 70, 1277
Cited by
Items 101–200 of 284
Adlimoghaddam, A., Odero, G. G., Glazner, G., Turner, R. S., & Albensi, B. C. (2021) · Aging and disease · doi:10.14336/ad.2020.0910 · Cited by 38
Hunn, B. H. M., Vingill, S., Threlfell, S., Alegre-Abarrategui, J., Magdelyns, M., Deltheil, T., Bengoa-Vergniory, N., Oliver, P. L., Cioroch, M., Doig, N. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.029 · Cited by 38
Clinical Trial Highlights: Targeting Alpha-Synuclein
McFarthing, K., & Simuni, T. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-189004 · Cited by 38
Wu, J., Xu, X., Li, Z., Mo, J., Jin, X., & Bao, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108025 · Cited by 38
Self-citationParkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
Pirooznia, S. K., Rosenthal, L. S., Dawson, V. L., & Dawson, T. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000189 · Cited by 37
Walsh, R. R., Damle, N. K., Mandhane, S. N., Piccoli, S. P., Talluri, R. S., Love, D. K., Yao, S., Ramanathan, V. K., & Hurko, O. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105281 · Cited by 35
Stevenson, M. E., Varghese, R. S., Hebron, M. L., Liu, X., Ratliff, N., Smith, A., Turner, R. S., & Moussa, C. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02802-0 · Cited by 35
Self-citationGreen, H., Tsitsi, P., Markaki, I., Aarsland, D., & Svenningsson, P. (2019) · CNS Drugs · doi:10.1007/s40263-018-0601-x · Cited by 33
Yañez, M. J., Marín, T., Balboa, E., Klein, A. D., Alvarez, A. R., & Zanlungo, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165875 · Cited by 33
Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy
Javidnia, M., Hebron, M. L., Xin, Y., Kinney, N. G., & Moussa, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170429 · Cited by 33
Self-citationAstrocytes and Alpha-Synuclein: Friend or Foe?
Ozoran, H., & Srinivasan, R. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230284 · Cited by 32
Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
Stott, S., Wyse, R. K. H., & Brundin, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653377 · Cited by 32
Drug Discovery and Development Targeting Dementia
Zagórska, A., Czopek, A., Fryc, M., Jaromin, A., & Boyd, B. J. (2023) · Pharmaceuticals · doi:10.3390/ph16020151 · Cited by 32
Antelope, O., Vellore, N. A., Pomicter, A. D., Patel, A. B., Scoyk, A. V., Clair, P. M., Deininger, M. W., & O’Hare, T. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.08.007 · Cited by 31
Progress toward an integrated understanding of Parkinson’s disease
Rousseaux, M. W. C., Shulman, J. M., & Jankovic, J. J. (2017) · F1000Research · doi:10.12688/f1000research.11820.1 · Cited by 30
CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
Fowler, A. J., Ahn, J., Hebron, M., Chiu, T., Ayoub, R., Mulki, S., Ressom, H. W., Torres-Yaghi, Y., Wilmarth, B., Pagan, F. L., et al. (2021) · Neurology Genetics · doi:10.1212/nxg.0000000000000633 · Cited by 30
Self-citationGenetic causes of PD: A pathway to disease modification
Toffoli, M., Vieira, S. R. L., & Schapira, A. H. V. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108022 · Cited by 29
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?
Sidoroff, V., Bower, P., Stefanova, N., Fanciulli, A., Stankovic, I., Poewe, W. H., Seppi, K., Wenning, G. K., & Krismer, F. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223183 · Cited by 29
Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations
Rodriguez‐Porcel, F. E., Wyman‐Chick, K. A., Abdelnour, C., Toledo, J. B., Ferreira, D., Urwyler, P., Weil, R. S., Kane, J. P. M., Pilotto, A., Rongve, A., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00299-w · Cited by 29
Guttuso, T. J., Andrzejewski, K. L., Lichter, D. G., & Andersen, J. K. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.05.016 · Cited by 29
New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics
Sardi, S. P., & Simuni, T. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.10.025 · Cited by 28
Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases
McAlary, L., Plotkin, S. S., & Cashman, N. R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00657-9 · Cited by 28
Autophagy and Redox Homeostasis in Parkinson’s: A Crucial Balancing Act
Jiménez-Moreno, N., & Lane, J. D. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8865611 · Cited by 28
Impaired autophagy in amyloid-beta pathology: A traditional review of recent Alzheimer's research
Yuan, M., Wang, Y., Huang, Z., Jing, F., Qiao, P., Zou, Q., Li, J., & Cai, Z. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20220145 · Cited by 27
Ahanger, I. A., & Dar, T. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102538 · Cited by 27
c-Abl activates RIPK3 signaling in Gaucher disease
Yañez, M. J., Campos, F., Marín, T., Klein, A. D., Futerman, A. H., Alvarez, A. R., & Zanlungo, S. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166089 · Cited by 26
Old wines in new bottles: Repurposing opportunities for Parkinson's disease
Kakkar, A. K., Singh, H., & Medhi, B. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.023 · Cited by 26
Emerging disease‐modifying strategies targeting α‐synuclein for the treatment of Parkinson's disease
O’Hara, D. M., Kalia, S. K., & Kalia, L. V. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14345 · Cited by 26
Hoyt, C. T., Domingo‐Fernándéz, D., & Hofmann‐Apitius, M. (2018) · Database · doi:10.1093/database/bay126 · Cited by 25
Nilotinib in Parkinson's disease: A systematic review and meta-analysis
Xie, X., Yuan, P., Kou, L., Chen, X., Li, J., & Li, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.996217 · Cited by 25
Fernández‐Valle, T., Gabilondo, I., & Gómez‐Esteban, J. C. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.06.014 · Cited by 24
Berg, S. Z., & Berg, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1228530 · Cited by 23
Precision Medicine in Parkinson’s Disease: From Genetic Risk Signals to Personalized Therapy
Straccia, G., Colucci, F., Eleopra, R., & Cilia, R. (2022) · Brain Sciences · doi:10.3390/brainsci12101308 · Cited by 22
Drug reprofiling history and potential therapies against Parkinson’s disease
Latif, K., Ullah, A., Shkodina, A. D., Boiko, D. I., Rafique, Z., Alghamdi, B. S. A., Alfaleh, M. A., & Ashraf, G. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1028356 · Cited by 22
Marín, T., Dulcey, A. E., Campos, F., de la Fuente, C., Acuña, M., Castro, J., Pinto, C., Yañez, M. J., Cortéz, C., McGrath, D. W., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.844297 · Cited by 22
The c-Abl inhibitor in Parkinson disease
Zhou, Z., Wu, Y., Wang, X.-M., & Han, Y. (2017) · Neurological Sciences · doi:10.1007/s10072-016-2808-2 · Cited by 22
Therapeutic innovation in Parkinson’s disease: a 2020 update on disease-modifying approaches
Colombo, D., Pnevmatikou, P., Melloni, E., & Keywood, C. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1800454 · Cited by 21
Höllerhage, M., Fussi, N., Rösler, T. W., Wurst, W., Behrends, C., & Höglinger, G. U. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.01.023 · Cited by 21
Heard, D. S., Tuttle, C. S. L., Lautenschlager, N. T., & Maier, A. B. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01520 · Cited by 20
Caught in the act: LRRK2 in exosomes
Wang, S., & West, A. B. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180467 · Cited by 20
From protein biomarkers to proteomics in dementia with Lewy Bodies
Tsamourgelis, A., Swann, P., Chouliaras, L., & O'Brien, J. T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101771 · Cited by 19
Drug Repurposing: Insights into Current Advances and Future Applications
Bhatia, T., & Sharma, S. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673266470231023110841 · Cited by 19
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 19
Dowaidar, M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/pdzqb · Cited by 19
The evolving therapeutic landscape of dementia with Lewy bodies
Kaila, L. V., Ikeda, M., Sultana, J., Chouliaras, L., O'Brien, J. T., & Taylor, J. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00323-0 · Cited by 18
Dementia with Lewy bodies: emerging drug targets and therapeutics
Pope, E. D., Cordes, L., Shi, J., Mari, Z. K., Decourt, B., & Sabbagh, M. N. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1916913 · Cited by 18
Wyse, R. K. H., Isaacs, T., Barker, R. A., Cookson, M., Dawson, T. M., Devos, D., Dexter, D. T., Duffen, J., Federoff, H. J., Fiske, B. K., et al. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230363 · Cited by 18
Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients
Anderson, K. E., Stevenson, M. E., Varghese, R. S., Hebron, M. L., Koppel, E., McCartin, M., Kuprewicz, R., Matar, S., Ferrante, D., & Moussa, C. (2022) · Metabolites · doi:10.3390/metabo12121225 · Cited by 18
Self-citationAutophagy and Its Association with Genetic Mutations in Parkinson Disease
Erekat, N. S. (2022) · Medical Science Monitor · doi:10.12659/msm.938519 · Cited by 17
Insights into the management of Lewy body dementia: a scoping review
Khan, S. A., Khan, S., Kausar, H., Shah, R. K., Luitel, A., Gautam, S., Parajuli, S. B., Rauniyar, V. K., & Khan, M. A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001664 · Cited by 17
Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease
Du, J., & Chen, S. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.211555 · Cited by 17
O'Brien, J. T., Chouliaras, L., Sultana, J., Taylor, J., Ballard, C. G., on behalf of the RENEWAL Study Group, Aarsland, D., Blanc, F., Boeve, B. F., Brooks, D. J., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01103-7 · Cited by 17
Self-citationProgress in the treatment of Parkinson-Plus syndromes
Olfati, N., Shoeibi, A., & Litvan, I. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.10.006 · Cited by 17
Lin, Y. W., & Truong, D. D. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.02.021 · Cited by 17
Outcome Measures for Dementia With Lewy Body Clinical Trials: A Review
Patel, B., Irwin, D. J., Kaufer, D., Boeve, B. F., Taylor, A., & Armstrong, M. J. (2021) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000473 · Cited by 17
Das, V., Miller, J. H., Goud, A. C., Annadurai, N., Sanctis, J. B. D., Hrubá, L., & Hajdúch, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22033 · Cited by 16
Kaiser, T. M., Dentmon, Z. W., Dalloul, C. E., Sharma, S. K., & Liotta, D. C. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00612 · Cited by 16
Novel approaches to counter protein aggregation pathology in Parkinson's disease
Stott, S., Wyse, R. K. H., & Brundin, P. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.007 · Cited by 16
Niacin for Parkinson's disease
Seamon, M., Purohit, S. B., Giri, B., Baban, B., Morgan, J. C., Chong, R. K. Y., & Wakade, C. G. (2019) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12553 · Cited by 16
Lona‐Durazo, F., Reynolds, R. H., Scholz, S. W., Ryten, M., & Taliun, S. A. G. (2023) · Communications Biology · doi:10.1038/s42003-023-05113-5 · Cited by 15
Recent Advances in Drug Repurposing for Parkinson’s Disease
Chen, X., Gumina, G., & Virga, K. G. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180719144850 · Cited by 15
Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy
Cuina, M. L., Guerin, P. A., Canron, M., Delamarre, A., Dehay, B., Bézard, E., Meissner, W. G., & Fernagut, P. (2020) · Movement Disorders · doi:10.1002/mds.28034 · Cited by 15
Drug repositioning for Parkinson’s disease: An emphasis on artificial intelligence approaches
Karimi-Sani, I., Sharifi, M., Abolpour, N., Lotfi, M., Atapour, A., Takhshid, M. A., & Sahebkar, A. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102651 · Cited by 14
Espay, A. J., Hauser, R. A., & Armstrong, M. J. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3983 · Cited by 14
Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson’s Disease
Jeong, S. H., & Lee, P. H. (2025) · Journal of Movement Disorders · doi:10.14802/jmd.25008 · Cited by 13
Bloom, A. N., Tian, H., Schoen, C. L., & Winograd, N. (2017) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-017-0262-5 · Cited by 13
Pulivarthi, C. B., Choubey, S. S., Pandey, S. K., Gautam, A. S., & Singh, R. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18677-6.00011-7 · Cited by 13
Repositioning of receptor tyrosine kinase inhibitors
Mansour, H. M., & El-Khatib, A. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18677-6.00010-5 · Cited by 13
Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing
Makeeva, V. S., Dyrkheeva, N. S., Lavrik, O. I., Zakian, S. M., & Malakhova, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316798 · Cited by 13
Roles for c-Abl in postoperative neurodegeneration
Feng, L., Fu, S., Yao, Y., Li, Y., Xu, L., Zhao, Y., & Luo, L. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.73740 · Cited by 12
Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches
Sayas, C. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00005-7 · Cited by 11
Challenges and Opportunities in Repurposing of Drugs: Mini Review
Sindhu, S., & Murugan, S. (2020) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v19i3.45851 · Cited by 11
Spatiotemporal analysis of soluble aggregates and autophagy markers in the R6/2 mouse model
Kumar, M., Shah, D., Giridharan, M., Yadav, N., Manjithaya, R. R., & Clement, J. P. (2021) · Scientific Reports · doi:10.1038/s41598-020-78850-w · Cited by 11
Emerging drugs for dementia with Lewy Bodies: a review of Phase II & III trials
Tolea, M. I., Ezzeddine, R., Camacho, S., & Galvin, J. E. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2244425 · Cited by 11
Federti, E., Mattè, A., Riccardi, V., Peikert, K., Alper, S. L., Danek, A., Walker, R. H., Siciliano, A., Iatcenko, I., Hermann, A., et al. (2021) · Antioxidants · doi:10.3390/antiox11010076 · Cited by 11
Faouzi, A., Arnaud, A., Hallé, F., Roussel, J., Aymard, M., Denavit, V., Do, C. V., Mularoni, A., Salah, M., ElHady, A. K., et al. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00537f · Cited by 10
Diarylamides in anticancer drug discovery: A review of pre-clinical and clinical investigations
Abduelkarem, A. R., Anbar, H. S., Zaraei, S., Alfar, A. A., Al-Zoubi, O. S., Abdelkarem, E. G., & El–Gamal, M. I. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112029 · Cited by 10
Pagán, F., Torres-Yaghi, Y. A., Hebron, M. L., Wilmarth, B., Turner, R. S., Matar, S., Liu, X., Ferrante, D., Esposito, G., Ahn, J., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124245 · Cited by 9
Self-citationGlucagon‐like Peptides (GLP‐1) Perspectives in Synucleinopathies Treatment
Foltynie, T., & Athauda, D. S. (2018) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12611 · Cited by 9
Etiology and pathogenesis of Parkinson disease
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00005-6 · Cited by 9
Lewy Body Dementia: An Overview of Promising Therapeutics
Skylar‐Scott, I. A., & Sha, S. J. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01292-0 · Cited by 9
Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies
Vijayakumar, D., & Jankovic, J. J. (2022) · CNS Drugs · doi:10.1007/s40263-022-00903-7 · Cited by 9
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Huang, C., Zheng, X., Yan, S., & Zhang, Z. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3341 · Cited by 8
The Search for Disease Modification in Parkinson’s Disease—A Review of the Literature
Barber, D., Wijeratne, T., Singh, L., Barnham, K. J., & Masters, C. L. (2025) · Life · doi:10.3390/life15081169 · Cited by 8
Sarva, H., Pahwa, R., Hernández‐Vara, J., Goldstein, M. A., Borgohain, R., Factor, S. A., Inamdar, S., Love, D. K., Hames, C., Fu, Y., et al. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01275-1 · Cited by 7
Elucidating the molecular targets in Alzheimer's disease: Advances and therapeutic implications
Soni, U., & Pujari, R. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111660 · Cited by 7
Zhou, Y., Yamamura, Y., Ogawa, M., Tsuji, R., Tsuchiya, K., Kasahara, J., & Goto, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01311 · Cited by 7
Therapeutic strategies for Parkinson’s disease: promising agents in early clinical development
Fabbri, M., Perez‐Lloret, S., & Rascol, O. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1814252 · Cited by 7
Disease modifying therapies for Parkinson's disease: Novel targets
Vijiaratnam, N., & Foltynie, T. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108839 · Cited by 7
The genetic background of Parkinson’s disease and novel therapeutic targets
Salamon, A., Zádori, D., Szpisjak, L., Klivènyi, P., & Vécsei, L. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2153037 · Cited by 7
Quantitative analysis of nasal transcripts reveals potential biomarkers for Parkinson’s disease
Kim, H., Kang, S., Jo, Y. M., Kim, M. S., Lee, Y., Cho, S. H., & Kim, H.-T. (2019) · Scientific Reports · doi:10.1038/s41598-019-47579-6 · Cited by 7
An update on clinical trials targeting human tauopathies
Moussa, C.-H., Javidnia, M., & Kurd-Misto, B. T. (2017) · Clinical Trials in Degenerative Diseases · doi:10.4103/2542-3975.216580 · Cited by 6
Self-citationDeveloping theragnostics for Alzheimer's disease: Insights from cancer treatment
Lee, H., Choi, H.-J., Jeong, Y. J., Na, Y., Hong, J. T., Han, J. M., Hoe, H., & Lim, K. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131925 · Cited by 6
Berton, G. G., Rodrigues, A. C. L. F., Borges, R. D. S., Cardoso, N. R., de Oliveira, T. A., & Marques, M. V. O. (2024) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000597 · Cited by 6
The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia
Lee, W. J., Moon, J., Kim, T., Jun, J., Lee, H. S., Ryu, Y. J., Lee, S., Jung, K., Park, K., Jung, K., et al. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.05.015 · Cited by 6
Emerging drugs for progressive supranuclear palsy
Giagkou, N., & Stamelou, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1609450 · Cited by 6
Targeting protein kinases in Parkinson’s disease: the emerging role of phytoconstituents
Joshi, D., Kulkarni, M., Parekh, P., Shah, S., Greig, N. H., & Acharya, S. P. (2025) · Nutritional Neuroscience · doi:10.1080/1028415x.2025.2531356 · Cited by 5
The next chapter in symptomatic Parkinson disease treatments
Hengartner, D., & Fernandez, H. H. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.01.002 · Cited by 5
Köllő, Z., Garami, M., Vincze, I., Vásárhelyi, B., & Karvaly, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010239 · Cited by 5
Metadata
- Authors
- Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., Lawler, A., Rogers, S. L., Falconer, R. A., Ahn, J., Li, Z., & Moussa, C.
- Affiliations
- Department of Neurology, National Parkinson’s Foundation Center for Excellence, Translational Neurotherapeutics Program. Movement Disorders Program. MedStar Georgetown Hospital Washington, DC, USA
- Georgetown University Medical Center (US)
- MedStar Georgetown University Hospital (US)
- Corresponding author
- Moussa, Charbel
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-06-03
- Volume
- 6
- Issue
- 3
- Pages
- 503-517
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC5008228
- OpenAlex
- W2462137239
- Cited by
- 265
- References
- 49
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 20 · 2023: 23 · 2022: 37 · 2021: 34 · 2020: 32 · 2019: 38 · 2018: 30 · 2017: 17 · 2016: 7
- FWCI
- 23.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health and Human Services (UL1RR031975)
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health (UL1TR001409, UL1TR000101)
- National Center for Research Resources (UL1RR031975)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- nilotinib, Parkinson's disease, dementia with Lewy bodies, ABL tyrosine kinase inhibitors, cerebrospinal fluid pharmacokinetics, target engagement, homovanillic acid, cerebrospinal fluid biomarkers, drug safety and tolerability
- MeSH terms
- Dementia, Follow-Up Studies, Humans, Parkinson Disease, Pyrimidines, Outcome Assessment, Health Care, Lewy Body Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.